[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"met-amplification\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:met-amplification":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,95,121],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100617758","phase-2-osimertinib-combined-with-savolitinib-in-the-treatment-of-nsclc-with-low-copy-number-met-amplification-100617758",false,"NCT07322783","Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification","Osimertinib Combined With Savolitinib in the Treatment of EGFR Mutated Osimertinib Resistant NSCLC With Low Copy Number MET Amplification","Inclusion Criteria:\n\n* 1\\. Histologically or cytologically confirmed incurable advanced or metastatic non-small cell lung cancer who resistant to resistant to osimertinib, chemo-immunotherapy or anti-angiogenesis.\n\n  2\\. At least 1 measurable lesion (RECIST 1.1). 3. MET amplification copy number below 5 by FISH. 4. Male or female patients age ≥18 years. 5. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2. 6. Estimated OS ≥3 months. 7. Adequate hematologic and bone marrow functions. 8. Adequate renal and liver function. 9. Had recovered from all toxicities related to prior anticancer therapies to grade ≤ 2, except for patients with grade 2 nausea\u002Fvomiting and\u002For grade 2 diarrhea despite optimal supportive therapy who will not be allowed to participate in the study.\n\n  10\\. Willingness to use contraception by a method that is deemed effective by the investigator by both males and female patients of child bearing potential (postmenopausal women must have been amenorrhea for at least 12 months to be considered of non-childbearing potential) and their partners throughout the treatment period and for at least three months following the last dose of study drug.\n\n  11\\. Ability to understand and willingness to sign a written informed consent form (the consent form must be signed by the patient prior to any study-specific procedures).\n\n  12\\. Willingness and ability to comply with study procedures and follow-up examination.\n\nExclusion13. Any of the following cardiac criteria: screening period resting period QTC \\> 470 milliseconds (clinical electrocardiograph report value; if a single time\\> 470 milliseconds, take the average of 3 inspections); rhythm of resting electrocardiogram (ECG), any clinically important abnormality of conduction or morphology (e.g., complete left bundle branch block, Grade 3 heart block, Grade 2 heart block); family history of congenital long QT prolongation syndrome or long QT syndrome.\n\n14\\. Evidence of any serious or uncontrolled systemic disease; various chronic active infections such as hepatitis B (HBV-DNA ≥ 104 copy number\u002Fml or 2000 IU\u002Fml), hepatitis C and HIV; uncontrollable Hypertensive patients (requires 2 or more drugs to control blood pressure); unstable angina; angina pectoris within 3 months prior to study; congestive heart failure (NYHA class II or higher); myocardial infarction (NSTEMI or STEMI) history in 6 months before study enrollment; severe arrhythmia requiring medical attention; severe liver, kidney, gastrointestinal or metabolic diseases.\n\n15\\. Patients who are unable to taking drugs 16. Other malignancies need treatment; except effectively treated skin basal cell carcinoma, cutaneous squamous cell carcinoma, and\u002For effectively resected orthotopic cervical cancer and\u002For breast cancer.\n\n17\\. Female patients during pregnancy or lactation. 18. Previous allergies or intolerance to treatment with osimertinib and savolitinib.\n\n19\\. Any other condition or circumstance of that would, in the opinion of the investigator, make the patient unsuitable for participation in the study.\n\nCriteria:\n\n\\-","ALL","18 Years","80 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Osimertinib combined with savolitinib in the treatment of EGFR mutated osimertinib resistant NSCLC with low copy number MET amplification There are unmet medical needs in patients who resist to to osimertinib; savolitinib plus osimertinib shows high response rate and prolong progression-free survival in high copy number MET amplification patients. This study is to explore the efficacy and safety of the combination of savolitinib and osimertinib in osimertinb resistant patients with low copy number MET amplification.",[27,28],"EGFR Positive Non-small Cell Lung Cancer","MET Amplification",[30,31,32],"Savolitinib","Osimertinib","Drug Resistant","RECRUITING","2025-12-29",{"date":36,"type":37},"2026-01-07","ACTUAL",{"date":39,"type":37},"2025-01-01",{"date":41,"type":21},"2026-12-31",{"name":43,"class":44},"Qingdao Central Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":76,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":94},"100299221","phase-2-apl-101-study-of-subjects-with-nsclc-with-c-met-exon-14-skip-mutations-and-c-met-dysregulation-advanced-solid-tumors-100299221","NCT03175224","APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","Phase 1 \u002F 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","SPARTA","Major Inclusion Criteria:\n\n1. Men and women 18 years of age or older.\n2. 9 cohorts will be enrolled:\n\n   * Cohort A1 \u002F Exon 14 NSCLC MET inhibitor naive in first line: Histologically or cytologically confirmed NSCLC with Exon 14 skipping mutations; all histologies; unresectable or metastatic disease (Stage 3b\u002F4); treatment-naive subjects in first line; not received any MET inhibitor and no known MET kinase inhibitor resistance mutations\n   * Cohort A2 \u002F Exon 14 NSCLC - MET inhibitor naïve: Histologically or cytologically confirmed NSCLC with Exon 14 skipping mutations; all histologies; unresectable or metastatic disease (Stage 3b\u002F4); pretreated subjects refractory to or intolerant of standard therapies with no more than three lines of prior therapy in the unresectable or metastatic setting; not received any MET inhibitor and no known MET kinase inhibitor resistance mutations\n   * Cohort B \u002F Exon 14 NSCLC MET inhibitor experienced: ENROLLMENT COMPLETED\n   * Cohort C \u002F MET amplification basket tumor types excluding primary CNS tumors: Any solid tumor type regardless of histology excluding primary CNS tumors, with MET amplification; unresectable or metastatic disease, refractory to or intolerant of standard therapies, or refused standard therapies, or if therapy was unavailable or unfeasible, with no more than 3 prior lines of therapy in the unresectable or metastatic setting; not received any MET inhibitor and no known MET kinase inhibitor resistance mutations\n   * Cohort C1 \u002F MET amplification and wild-type EGFR NSCLC: NSCLC regardless of histology, harboring MET amplification and wild-type EGFR; unresectable or metastatic disease, previously untreated or treated with no more than 3 prior lines of therapy in the unresectable or metastatic setting; not received any MET inhibitor and no known MET kinase inhibitor resistance mutations\n   * Cohort C2 \u002F EGFR positive NSCLC with acquired MET amplification (APL-101 Add-on Therapy): Unresectable or metastatic NSCLC regardless of histology, harboring EGFR activating mutations with acquired MET-Amplification as resistance mechanism to the EGFR-I; developed resistance to first-line EGFR-inhibitor therapy after an initial response (documented PR for at least 12 weeks); radiological documentation of disease progression per RECIST on first-line EGFR inhibitor therapy; currently on an EGFR-inhibitor therapy and agrees to receive APL-101 as an add-on therapy during the study; no history of interstitial lung disease (ILD)\u002Fpneumonitis, Grade ≥3 liver toxicity or QT prolongation with EGFR-I therapy; not received any MET inhibitor and no known MET kinase inhibitor resistance mutations\n   * Cohort D \u002F MET fusion basket tumor types excluding primary CNS tumors: any solid tumor type regardless of histology excluding primary CNS tumors; unresectable or metastatic disease, refractory to or intolerant of standard therapies, or refused standard therapies, or if therapy was unavailable or unfeasible, with no more than 3 prior lines of therapy in the unresectable or metastatic setting; not received any MET inhibitor and no known MET kinase inhibitor resistance mutations\n   * Cohort E \u002F Primary CNS tumors with MET alterations: subjects with primary CNS tumors who meet inclusion criteria of MET dysregulations defined as single or co-occurred MET fusion including PTPRZ1-MET (ZM) fusion, MET Exon 14 skipping mutations, or MET amplification; refractory to or intolerant of standard therapies, or refused standard therapies, or if therapy was unavailable or unfeasible, with no more than 3 prior lines of therapy in the unresectable or metastatic setting; not received any MET inhibitor and no known MET kinase inhibitor resistance mutations; neurological symptoms controlled on a stable\u002Fdecreasing dose of steroids for at least 2 weeks before C1D1\n   * Cohort F \u002F Basket tumor types harboring wild-type MET with over-expression of HGF and MET: any solid tumor type regardless of histology harboring wild-type MET with overexpression of HGF and MET; Unresectable or metastatic disease, refractory to or intolerant of standard therapies, or refused standard therapies, or if therapy was unavailable or unfeasible, with no more than 3 prior lines of therapy in the unresectable or metastatic setting; not received any MET inhibitor and no known MET kinase inhibitor resistance mutations\n3. Treated or untreated asymptomatic parenchymal CNS disease or leptomeningeal disease is allowed.\n4. Presence of ≥1 measurable lesion (scan done ≤28 days of C1D1) to serve as target lesion according to relevant criteria\n5. ECOG performance status of 0-1. For subjects with primary CNS tumors, KPS score ≥70.\n6. Acceptable organ function\n7. For all prior anticancer treatment, a duration of 30 days or 5 half-lives of the agents used, whichever is shorter, must have elapsed, and any encountered toxicity must have resolved to levels meeting all the other eligibility criteria prior to the first dose of study treatment. Palliative radiotherapy to non-target lesions should be completed within 2 weeks prior to APL-101 administration.\n8. Adequate cardiac function\n9. Women of child-bearing potential must have a negative serum or Beta-hCG at screening or evidence of surgical sterility or evidence of post-menopausal status\n10. No planned major surgery within 4 weeks of first dose of APL-101\n11. Expected survival (life expectancy) ≥ 3 months from C1D1\n12. Provision of sample; e.g. archival or a fresh tumor biopsy sample (if safe and feasible) either from the primary or a metastatic site) or liquid biopsy sample (if tumor tissue is insufficient or lacking, and approved by the sponsor) is required for prospective central lab confirmation for study entry (subjects with previously confirmed molecular status by the Sponsor designated central lab or FDA approved NGS based MET testing may be exempted, subjected to Sponsor approval.\n\nMajor Exclusion Criteria:\n\n1. Hypersensitivity to APL-101, excipients of the drug product, or other components of the study treatment regimen.\n2. Known actionable mutation\u002Fgene rearrangement of EGFR (except for NSCLC subjects in Cohort C and C-2), ALK, ROS1, RET, NTRK, KRAS, and BRAF.\n3. Use or intended use of any other investigational product, including herbal medications, through Study Treatment Termination.\n4. Active uncontrolled systemic bacterial, viral, or fungal infection or clinically significant, active disease process, which in the opinion of the investigator makes the risk: benefit unfavorable for the participation of the trial.\n5. Life-threatening illness, significant organ system dysfunction or comorbid conditions, or other reasons that, in the investigator's opinion, could compromise the subject's safety or the integrity of the study outcomes, or interfere with the absorption or metabolism of APL-101.\n6. Unstable angina or myocardial infarction within 1 year prior to first dose of APL-101, symptomatic or unstable arrhythmia requiring medical therapy, history of congenital prolonged QT syndrome, prolonged QT interval corrected by Fridericia formula (QTcF) at screening, or concurrent treatment with a medication that is a known risk for prolonging the QT interval. Chronic controlled atrial fibrillation is not excluded.\n7. Historical seropositive results consistent with active infection for hepatitis C virus (HCV) or hepatitis B virus (HBV) with high viral loads not actively managed with antiviral therapy and human immunodeficiency virus (HIV) positive subjects who are not clinically stable or controlled on their medication (asymptomatic subjects with CD4+ T-cell (CD4+) counts ≥ 350 cells\u002FμL and have not had an opportunistic infection within the past 12 months prior to first dose of APL-101 would be eligible for study entry. If history is unclear, relevant test(s) at Screening will be required to confirm eligibility.\n8. Known significant mental illness or other conditions such as active alcohol or other substance abuse that, in the opinion of the investigator, predisposes the subject to high risk of noncompliance with the protocol treatment or assessments.\n9. Unable to swallow orally administered medication whole.\n10. Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter drug absorption\n11. Women who are breastfeeding\n12. History of another malignancy within 3 years prior to C1D1. A subject with the following malignancies is allowed if considered cured or unlikely to recur within 3 years:\n\n    1. Carcinoma of the skin without melanomatous features.\n    2. Curatively treated cervical carcinoma in situ.\n    3. Bladder tumors considered superficial such as noninvasive (T1a) and carcinoma in situ (T1s), thyroid papillary cancer with prior treatment, prostate cancer which has been surgically or medically treated and not likely to recur within 3 years.\n13. Subjects who are unable or unwilling to discontinue excluded medications (drugs with known QTc risk and known strong cytochrome P450 \\[CYP\\]3A4 inducer and\u002For strong inhibitors) for at least 5 half-lives prior to first dose of study drug. Subjects may qualify if such medication(s) can be safely replaced with alternate medications with less risk of drug-drug interaction.\n14. Subjects with active COVID-19 infection.\n15. Symptomatic and\u002For neurologically unstable CNS metastases, or who require an increase in steroid dose to control CNS disease. Subjects who have been receiving a stable steroid dose for at least 2 weeks prior to C1D1 may be allowed.",{"count":55,"type":21},497,[24],"To assess:\n\n* efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET\n* efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resistance with MET amplification and disease progression after documented CR or PR with 1st line EGFR inhibitors (EGFR-I)",[59,60,61,62,63,64,65,66,67,68,28,69,70,71,72,73,74,75],"Solid Tumors","Advanced Cancer","Renal Cancer","Gastric Cancer","Gastroesophageal Junction Adenocarcinoma","NSCLC","Lung Cancer","Brain Tumor","Glioblastoma Multiforme","EGFR Gene Mutation","HGF","Thyroid Cancer","Pancreatic Cancer","Colon Cancer","MET Alteration","MET Fusion","Exon 14 Skipping",[77,78,79,80,81,82,69,83],"Advanced Solid Tumor","Relapsed Solid Tumor","Recurrent Solid Tumor","cMet exon 14 skipping","cMet fusion","GBM","EGFR positive","2025-06-24",{"date":86,"type":37},"2025-06-27",{"date":88,"type":37},"2017-09-27",{"date":90,"type":21},"2026-11-30",{"name":92,"class":93},"Apollomics Inc.","INDUSTRY",35,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":105,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":45},"100524502","phase-1-the-efficacy-and-safety-of-lmv-12-combined-with-osimertinib-in-nsclc-100524502","NCT06109558","The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC","A Prospective Clinical Research of Efficacy and Safety of LMV-12(HE003) Combined With Osimertini in the Treatment of Advanced Non-small Cell Lung Cancer That Has Previously Failed From EGFR Inhibitor Therapy","PROFILE","Inclusion Criteria:\n\n* Eligible subjects selected for this study must meet all of the following criteria:\n\n  1. Sign written informed consent before implementing any trial-related procedures;\n  2. Age ≥18 years old;\n  3. No limit on the gender;\n  4. Histological or cytological confirmed advanced or metastatic non-small cell lung cancer, ineligible for radical surgery, relapse after failure of previous treatment with first-line (including first, second, and third generation)EGFR inhibitors.\n\n     Cohort A：MET amplification,(by FISH, NGS or IHC) Cohort B：RET fusion.\n  5. Laboratory tests for organ function levels must meet the following requirements:\n\n     1. Absolute neutrophil count ≥ 1.5 × 109\u002FL;\n     2. Platelet count ≥ 100 × 109\u002FL;\n     3. Hemoglobin ≥ 9 g\u002FdL;\n     4. Bilirubin ≤1.5 times ULN; e) AST and ALT ≤2.5 times ULN (total bilirubin ≤3 times the upper limit of normal and AST and ALT ≤5 times the upper limit of normal are permitted if hepatic metastases are present);\n\n     f) Serum creatinine ≤ 1.5 times ULN or creatinine clearance ≥ 60 mL\u002Fmin (according to the Cockcroft-Gault formula);\n  6. For premenopausal women of childbearing potential a pregnancy test must be performed within 7 days prior to initiation of treatment, a serum pregnancy test must be negative, and they must be non-lactating; all enrolled patients (whether male or female) should use adequate barrier contraception throughout the treatment period and for 3 months after completion of treatment.\n\nExclusion Criteria:\n\n1. Subjects treated with CYP isozyme inducers or inhibitors (see Appendix 4 for details) within 3 weeks prior to enrollment;\n2. Pregnant or lactating women;\n3. History of immunodeficiency or other acquired, congenital immunodeficiency diseases;\n4. Patients with prior bone marrow transplantation or prior solid organ transplantation;\n5. Patients with a combination of gastrointestinal perforation, gastrointestinal fistula, or non-gastrointestinal fistula;\n6. Prior history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid therapy, or any evidence of clinically active interstitial lung disease.\n7. Hepatitis B, hepatitis C, or human immunodeficiency virus (HIV-positive). Hepatitis B is eligible for this study at \\\u003C500 IU\u002FmL (or 2500 cps\u002FmL) by quantitative HBV-DNA testing, and hepatitis C (HCV) antibody-positive patients are eligible for this study only if the polymerase chain reaction shows HCV RNA negativity;\n8. Fulfillment of any of the following cardiac criteria: (i) Bazetts' mean corrected QT interval (QTc) derived from electrocardiogram (ECG) examination at rest \\>470 msec (women) or \\>450 msec (men) (in the case of the 1st abnormality, retested once within 48 h and calculated by averaging the results of the 2 times); and (ii) a wide variety of clinically significant rhythmic, conduction, and resting ECG morphologic Abnormalities, such as complete left bundle branch block, grade III conduction block, grade II conduction block, PR interval \\>250 msec; (iii) Myocardial ischemia or myocardial infarction of grade I or higher, or congestive heart failure of grade ≥2 (New York Heart Association (NYHA) classification); (iv) Factors that may increase the risk of prolongation of QTc or the risk of arrhythmic events, such as coronary artery disease, heart failure hypokalemia, congenital long QT syndrome, family history of a first-degree relative with long QT syndrome or sudden unexplained death before the age of 40, and ongoing use of any medication known to prolong the QT interval;",{"count":104,"type":21},120,[106,24],"PHASE1","This is an open-label, single-arm, dose-escalation, multicenter phase I\u002FII clinical trial. The primary endpoints of this study were to evaluated the safety, tolerability, pharmacokinetic profile and preliminary efficacy of HE003 in combination with osimertinib in patients with advanced solid tumors who have failed previous standard therapy. The secondary endpoints of this study were to evaluated the efficacy HE003 in combination with osimertinib in patients with advanced solid tumors who have failed previous standard therapy.",[109,110,28,111],"Non Small Cell Lung Cancer","RET Gene Mutation","EGF-R Positive Non-Small Cell Lung Cancer","2024-05-28",{"date":114,"type":37},"2024-05-30",{"date":116,"type":37},"2023-12-31",{"date":118,"type":21},"2027-07-30",{"name":120,"class":44},"Hunan Province Tumor Hospital",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":131,"conditions":132,"keywords":138,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":146,"leadSponsor":147,"locationsCount":45},"100500752","phase-2-neoadjuvant-immunotherapy-in-rare-mutations-localized-nsclc-100500752","NCT05800340","Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC","Neoadjuvant Toripalimab Combined With Chemotherapy in Rare Mutations Stage IIB-IIIB NSCLC","Inclusion Criteria:\n\n1. Age: 18 Years and older\n2. ECOG physical score 0-1 points; expected survival time ≥ 3 months;\n3. Pathologically confirmed diagnosis with Stage IIB-IIIB NSCLC which harbored rare driver alteration including RET fusions, BRAF (V600E or non-V600E but confirmed driver mutations), ERBB2 exon20 insertion, MET amplification (FISH confirmed) or exon 14 skipping. Suspected N2 disease should be confirmed by either mediastinoscopy or EBUS. N1 disease could be determined through PET\u002FCT but biopsy of primary lung cancer is needed;\n4. Lung function capacity capable of tolerating the proposed lung surgery\n5. Available tissue of tumor for PD-L1 test\n6. Subjects voluntarily joined the study and signed informed consent, with good compliance to follow-up.\n\nExclusion Criteria:\n\n1. Stage I and stage IV NSCLC;\n2. Patients who have previously used any other anti-tumor drugs or radiotherapy;\n3. Large panel NGS indicated sensitive EGFR alteration, ALK fusion, ROS1 fusion or any other driver mutations combined with MDM2\u002FMDM4 amplification;\n4. Histologically confirmed small cell lung cancer (including lung cancer mixed with small cell lung cancer and non-small cell lung cancer);\n5. A history of active bleeding within the 6 months before enrollment, or receiving thrombolysis or anticoagulant therapy, or the investigator believes that there is a clear tendency to gastrointestinal bleeding (such as esophageal varices with bleeding risk, local activity) Ulcer lesions, etc.) or active hemoptysis;\n6. Patients with any underlying disease that investigators consider it may affect patient's prognosis including sever cardiovascular, pulmonary disease or serious infections; Clinically obvious gastrointestinal abnormalities, which may affect the intake, transport or absorption of drugs (such as inability to swallow, chronic diarrhea, intestinal obstruction, etc.), or patients with total gastrectomy;\n7. Known or suspected autoimmune disease with activity. Participants may be enrolled if they have type 1 diabetes, hypothyroidism that requires only hormone replacement therapy, skin diseases that require no systemic treatment (such as purpura, psoriasis, or hair loss), or other conditions that are not expected to return without external trigger.\n8. Patients with active hepatitis B (positive for HBsAg) or hepatitis C (positive for HCV RNA).\n9. Patients with human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)\n10. Patients with other active malignancies within five years\n11. Pregnant or lactating women; those who have fertility are unwilling or unable to take effective contraceptive measures;\n12. Patients with low compliance or willingness to take the drugs and surveillance.",{"count":129,"type":21},30,[24],"Phase II, single-arm, open-label single center study that assess clinical feasibility and safety of 3 cycles neoadjuvant Toripalimab plus chemotherapy in rare mutations stage IIB-IIIB NSCLC followed by optional adjuvant treatment upon investigators' decisions.",[133,134,135,136,28,137],"Non-Small Cell Lung Cancer","RET Driver Mutation","BRAF V600 Mutation","Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation","MET Exon 14 Skipping Mutation",[139,140,141],"Non-small Cell Lung Cancer","Neoadjuvant immunotherapy","Rare Mutations","2023-04-04",{"date":144,"type":37},"2023-04-05",{"date":142,"type":37},{"date":41,"type":21},{"name":148,"class":44},"Guangdong Provincial People's Hospital"]